BTIG Research Begins Coverage on Stoke Therapeutics (NASDAQ:STOK)

BTIG Research assumed coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a research report report published on Tuesday morning, The Fly reports. The brokerage issued a buy rating and a $46.00 price objective on the stock.

A number of other brokerages have also recently commented on STOK. HC Wainwright initiated coverage on Stoke Therapeutics in a research report on Friday, October 25th. They set a buy rating and a $30.00 price target for the company. Cowen reaffirmed a buy rating on shares of Stoke Therapeutics in a research report on Thursday, August 15th. Zacks Investment Research raised Stoke Therapeutics from a hold rating to a buy rating and set a $23.00 price target for the company in a research report on Wednesday, October 16th. JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a research note on Monday, July 15th. They set an overweight rating and a $34.00 price objective for the company. Finally, Canaccord Genuity began coverage on Stoke Therapeutics in a research note on Monday, July 15th. They set a buy rating and a $44.00 price objective for the company. Seven analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and a consensus target price of $35.33.

NASDAQ STOK traded down $2.59 during midday trading on Tuesday, hitting $23.32. 196,700 shares of the company traded hands, compared to its average volume of 127,135. The firm has a 50-day simple moving average of $24.15. Stoke Therapeutics has a 52 week low of $19.21 and a 52 week high of $39.04.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.26) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.01. As a group, analysts forecast that Stoke Therapeutics will post -2.09 EPS for the current year.

In related news, major shareholder Rtw Investments, Lp acquired 68,783 shares of Stoke Therapeutics stock in a transaction on Friday, November 1st. The stock was acquired at an average price of $29.89 per share, for a total transaction of $2,055,923.87. Insiders have acquired a total of 205,216 shares of company stock valued at $5,771,421 in the last quarter.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STOK. Platinum Investment Management Ltd. purchased a new position in shares of Stoke Therapeutics during the 2nd quarter valued at about $29,000. Strs Ohio purchased a new position in shares of Stoke Therapeutics during the 3rd quarter valued at about $51,000. Victory Capital Management Inc. purchased a new position in shares of Stoke Therapeutics during the 2nd quarter valued at about $73,000. Ladenburg Thalmann Financial Services Inc. purchased a new position in shares of Stoke Therapeutics during the 2nd quarter valued at about $88,000. Finally, Morgan Stanley purchased a new position in shares of Stoke Therapeutics during the 2nd quarter valued at about $104,000. Institutional investors and hedge funds own 43.28% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Featured Story: Understanding Market Liquidity

The Fly

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.